文献速递神经肿瘤

他拉泊芬钠光动力疗法治疗2/3级脑膜瘤的初步研究

Photodynamic therapy using talaporfin sodium for grade 2/3 meningiomas: a preliminary study of safety, feasibility, and clinical outcomes.
PubMed 文献 · J Neurooncol · 2026-03-31

本研究回顾性分析19例2/3级脑膜瘤患者,在切除联合他拉泊芬钠光动力疗法(PDT)后的可行性、安全性与临床结局。中位无进展生存期为12.5个月,PDT后中位总生存期为54.5个月;既往无放疗患者预后优于有放疗史者。结论认为PDT联合切除是安全辅助策略,对放疗后复发疗效有限,但在放疗前应用可能延缓进展。

要点

  • 2/3级脑膜瘤切除联合他拉泊芬钠PDT安全可行。
  • 中位无进展生存期12.5个月,PDT后中位总生存期54.5个月。
  • 无放疗史患者预后优于有放疗史者。

核心结论

  • PDT联合切除是2/3级脑膜瘤的安全辅助策略。
  • 初步数据显示PDT对放疗后复发疗效有限,但在放疗前应用可能延缓疾病进展。
  • PDT应被视为2/3级脑膜瘤的治疗选择之一。

研究设计与样本

  • 回顾性分析2015年至2025年在本机构接受切除联合PDT的19例2/3级脑膜瘤患者。
  • PDT在静脉给予他拉泊芬钠后22至26小时进行。
  • 回顾肿瘤位置、病理、Simpson切除分级、放疗史及结局。

主要发现

  • 19例中18例为复发肿瘤,10例有既往放疗史。
  • 肿瘤部位包括颅底8例、矢状窦旁6例、凸面2例、大脑镰1例、皮下1例、脑室内1例。
  • 组织学为2级12例、3级7例;Simpson I级3例、II级6例、III级2例、IV级8例。
  • 中位无进展生存期为12.5个月,PDT后中位总生存期为54.5个月。
  • 无放疗史患者预后优于PDT前有放疗史者。

临床怎么用

  • 对于2/3级脑膜瘤,可考虑在切除基础上联合他拉泊芬钠PDT作为辅助治疗。
  • 在放疗前应用PDT可能更有助于延缓疾病进展。
  • 对放疗后复发的患者,PDT疗效可能有限,需个体化评估。

局限性

  • 本研究为回顾性分析,样本量较小(19例)。
  • 结果为初步数据,需进一步研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Atypical and anaplastic (grade 2/3) meningiomas are associated with high recurrence rates and lack effective systemic therapies other than radiotherapy. Photodynamic therapy (PDT) using talaporfin sodium (TPS) generates selective cytotoxicity extending beyond resection margins and may improve local tumor control. Objective is to evaluate the feasibility, safety, and clinical outcomes of additional intraoperative PDT using TPS for grade 2/3 meningioma patients. METHODS: Nineteen patients with grade 2/3 meningiomas who underwent resection together with PDT at our institute between 2015 and 2025 were retrospectively analyzed. PDT was performed 22 to 26 h after intravenous TPS administration. Tumor location, pathology, Simpson resection grades, history of radiation therapy (RT), and outcomes were reviewed. RESULTS: Of the 19 patients, 18 had recurrent tumors, and 10 had prior RT. Tumor sites included skull base (8 patients), parasagittal sinus (6), convexity (2), falx (1), subcutaneous (1), and intraventricular (1). Histology revealed grade 2 (12 patients) and grade 3 (7), with Simpson I (3), II (6), III (2), and IV (8) resections. Median progression-free survival was 12.5 months, and median overall survival after PDT was 54.5 months. The prognosis was more favorable in RT- naïve patients than in those with a history of prior RT before PDT. CONCLUSION: PDT combined with resection is a safe adjunctive strategy for grade 2/3 meningiomas. Our preliminary data suggest that its efficacy is limited in post-radiation recurrences, but it may delay disease progression when applied before RT. PDT should hence be considered as a therapeutic option for grade 2/3 meningiomas.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Fukami S, Akimoto J, Nagai K, et al. Photodynamic therapy using talaporfin sodium for grade 2/3 meningiomas: a preliminary study of safety, feasibility, and clinical outcomes. J Neurooncol. 2026. PMID: 41917547. doi:10.1007/s11060-026-05550-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。